Fast on the heels of naming a new chief executive earlier this summer, Fujifilm Diosynth Biotechnologies said it's rolling out a new business structure to support customers of various sizes.
The company's "large-scale" strategic business unit (SBU) will be headed by Kenneth Bilenberg, executive vice president, and operates out of the CDMO’s biopharma manufacturing campus in Hillerød, Denmark, and its Holly Springs, North Carolina, facility. The latter site is currently under construction.
The two campuses are the "largest end-to-end, large scale cell culture facilities in both North America and Europe," the company said in a release.
With this business unit, Fujifilm Diosynth will support customers with large volume needs "utilizing multiples of 20,000 (liter) bioreactors," the company said.
Overseeing small-scale production, meanwhile, is Fujifilm Diosynth Executive Vice President Lee Kingsbury. This unit features sites in Teesside, U.K., plus in North Carolina, Texas, Massachusetts and California.
The small-scale SBU will support customers as they move through various stages of R&D and toward regulatory approval.
The company's new operating model will "create long-term value for our customers and allow us to cultivate mutually beneficial partnerships and maximize efficiencies across our network,” CEO Lars Petersen said in a release.
Petersen, who previously served as the CDMO’s chief operating officer at its site in Hillerød, Denmark, was named CEO in June. He succeeded Martin Meeson, who led the company since 2020.
Meanwhile, Peter Dam Madsen has been named vice president of the company's newly formed Strategy and Executive Office. This office is tasked with planning for future growth and identifying opportunities in the market.
Before joining Fujifilm Diosynth earlier this year, Madsen served for 15 years at Novo Nordisk in various leadership positions.
Fujifilm Diosynth recently set a goal of generating 200 billion yen ($1.4 billion) in annual sales by its fiscal year ending in March 2025.
Beyond fiscal year 2026, the company is aiming to hit a 20% annual growth rate with its Bio CDMO business by introducing new process capabilities, adding in-house capacity and supporting customers with its mammalian production capacity.